KELOIDS TREATMENT USING TRIPLE MEDICINE COMBINATION
Article PDF

Keywords

keloids, triple medicine combination treatment, glucocorticoids, 5-fluorouracil, hyaluronidase, scars chemotherapy, telangiectasia

Abstract views: 781
PDF Downloads: 486

How to Cite

Teplyi, V., & Grebchenko, K. (2018). KELOIDS TREATMENT USING TRIPLE MEDICINE COMBINATION. Medical Science of Ukraine (MSU), 14(1-2), 40-48. https://doi.org/10.32345/2664-4738.1-2.2018.06

Abstract

Relevance. A lot of conservative approaches have been proposed to the management of keloids, but none of them provides a guaranteed positive result and a stable absence of relapse.

Objective: to evaluate the effectiveness and side effects of triple keloid scar therapy.

Materials and methods. Thirty-three patients aged 18-69 years, who received treatment of keloids by triple medicine combination therapy, were investigated retrospectively. All patients were divided into two groups. In first one (16 patients) intralesional injections of mixture of 5-fluorouracil, triamcinolone acetonide and bovine origin hyaluronidase were performed. In the second group (17 patients) instead of triamcinolone betamethasone suspension was used. Four sessions of therapy were performed with a monthly interval. Results were assessed 1 month and 6 months after the last session. The planimetric investigation and measurement of scars’ volume were performed. The influence of treatment on the number of telangiectasias within the scar was performed with the help of our method of computer processing of its digital photographs.

Results. There was not statistically significant difference in linear size, area and volume of the scars in patients of two groups before beginning of the treatment. One month after the fourth session scars’ width increased statistically significantly. Their length and area also increased but difference did not reach statistically significant level. At the same time maximal height of the scars over surrounding tissues (p<0.001) and their volume (p=0.012 та 0.001) reduced significantly in both groups. There was not difference in percentage of scar volume reduction ((67.4±18.01) % and (74.3±14.71) % correspondingly, p=0.308) in different groups. The main negative effect of treatment was redness of the scars due to purpura and increase of telangiectasias number. Reliable increase of the part of the scars’ surface taken by the telangiectasias was registered in both groups without difference between them. Despite the overall improvement in self-esteem, the patients noted that the change in the color of the scar after the treatment came into the first plane among the factors causing aesthetic dissatisfaction. Supplementary methods of telangiectasias and hyperemia correction were used in 12 patients of the first and 11 patients of the second group. Pain syndrome and itching were eliminated in 11 out of 14 (78.6%) patients in the first group and in 11 out of 15 (73.3%) patients in the second group (p = 0.753). Performed treatment positively influenced patients’ quality of life. Their self-esteem increased essentially ((3.4±2.16) points, p=0.005 and (3.2±1.92) points, p=0.001 correspondingly). At re-examination 6 months after the termination of triple therapy, no statistically significant changes in the size of scars were found, pain and itching did not restore. The quality of life self-esteem remained unchanged.

Conclusion. The combined use of 5-fluorouracil, glucocorticoid, and hyaluronidase reduced the protrusion and volume of not-burn keloids in patients of both groups (by (67.4 ± 18.01) % and (74.3 ± 14.71) % respectively (p = 0.308)). Triple medicine therapy permitted to eliminate the pain syndrome and itching in 78.6 % of patients of group where triamcinolone acetonide was used, and in 73.3% of patients who received mixture that included betamethasone suspension (p=0.753). Triple medicine therapy effectiveness, both in term scars’ resizing, and eliminating clinical symptoms and improving the quality of life, was the same for both variants of the combination of drugs. The main side effect, that somewhat worsened the aesthetic result of treatment, was the increase of telangiectasias number. The part of the scar area taken by telangiectasias increased from the (3.4±1.16) % to the (9.7±3.51) %, p<0.001 in the first group and from the (3.3±1.31) % to the (9.7±3.05) %, p<0.001 in the second one. The use of glucocorticoid in triple therapy, which to a lesser extent will stimulate the formation of telangiectasias, will improve the cosmetic result of the treatment.

https://doi.org/10.32345/2664-4738.1-2.2018.06
Article PDF

References

Шаробаро В.И., Романец О.П., Гречишникова М.И., Баева А.А. Методы оптимизации лечения и профилактики рубцов // Хирургия. 2015. № 9. С.85-90.

Abeck D. Topical corticosteroids in dermatologic practice. High level of therapeutic safety, diverse fields of application and new developments // Hautnahdermatologie. 2014. Vol. 30. P. 1-4

Ahuja R.B., Chatterjee P. Comparative efficacy of intralesional verapamil hydrochloride and triamcinolone acetonide in hypertrophic scars and keloids // Burns. 2014. Vol. 40, № 4. P.583-588. doi.org/10.1016/j.burns.2013.09.029

Asilian A., Darougheh A., Shariati F. New combination of triamcinolone, 5-fluoruracil, and pulsed-dye laser for the treatment of keloid and hypertrophic scars // Dermatol. Surg. 2006. Vol. 32, № 7. P.907-915. doi.org/10.1111/j.1524-4725.2006.32195.x

Balci D.D., Inandi T., Dogramaci C.A., Celik E. DLQI scores in patients with keloids and hypertrophic scars: a prospective case control study // J. Dtsch. Dermatol. Ges. 2009. Vol. 7, № 8. P.688-692. doi.org/10.1111/j.1610-0387.2009.07034.x.

Basra M.K.A., Fenech R., Gatt R.M., Salek M.S., Finlay A.Y. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results // Br. J. Dermatol. 2008. Vol. 159. P. 997-1035. doi.org/10.1111/j.1365-2133.2008.08832.x

Brewin M.P., Lister T.S. Prevention or treatment of hypertrophic burn scarring: a review of when and how to treat with the pulsed dye laser // Burns. 2014. Vol. 40. P. 797. doi.org/10.1016/j.burns.2013.12.017

Brown B.C., Moss T.P., Mc Grouther D.A., Bayat A. Skin scar preconceptions must be challenged: importance of self-perception in skin scarring // J. Plast. Reconstr. Aesthet. Surg. 2010. Vol. 63, №6. P. 1022-1029. doi.org/10.1016/j.bjps.2009.03.019

Coondoo A., Phiske M., Verma S., Lahiri K. Side-effects of topical steroids: A long overdue revisit // Indian Dermatol. Online J. 2014. Vol. 5, № 4. P. 416-425. doi.org/10.4103/2229-5178.142483

Davison S.P., Mess S., Kauffman L.C., Al-Attar A. Ineffective treatment of keloids with interferon alpha-2b // Plast. Reconstr. Surg. 2006. Vol. 117, № 1. P.247-252. doi.org/10.1097/01.prs.0000195079.03742.cf

Goyal N.N., Gold M.H. A Novel Triple Medicine Combination Injection for the Resolution of Keloids and Hypertrophic Scars // J. Clin. Aesthet. Dermatol. 2014. Vol. 7, № 11. P.31-34.

Gual A., Pau-Charles I., Abeck D. Topical Corticosteroids in Dermatology: From Chemical Development to Galenic Innovation and Therapeutic Trends // Journal of Clinical & Experimental Dermatology Research. 2015. Vol. 6, № 2. doi.org/10.4172/2155-9554.1000269

Gurtner G., Neligan P. Plastic Surgery E-Book: Principles, third edition // Elsevier, 2013, Vol. 1. 702 p., URL: https://books.google.com.ua/books

Hahn J.M., Glaser K., McFraland K.L., Aronow B.J., Boyce S.T., Supp D.M. Keloid-derived keratinocytes exhibit an abnormal gene expression profile consistent with a distinct causal role in keloid pathology // Wound Repair Regen. 2013. Vol. 21, № 4. P.530-544. doi.org/10.1111/wrr.12060

Hengge U.R., Ruzicka T., Schwartz R.A., Cork M.J. Adverse effects of topical glucocorticosteroids // J. Am. Acad. Dermatol. 2006. Vol. 54. P. 1-18. doi.org/10.1016/j.jaad.2005.01.010

Huang C., Ogawa R. Roles of lipid metabolism in keloid development // Lipids Health Dis. 2013. Vol. 12. P. 1-6. doi.org/10.1186/1476-511x-12-60

Huang L.P., Wang G.Q., Jia Z.S., Chen J.W., Wang G., Wang X.L. Paclitaxel reduces formation of hypertrophic scars in the rabbit ear model // Therapeutics and Clinical Risk Management. 2015. Vol. 2015, № 11. P. 1089-1095. doi.org/10.2147/tcrm.s82961

Kant S. B., van den Kerckhove E., Colla C., Tuinder S., van der Hulst R.R.W.J., Piatkowski de Grzymala A.A. A new treatment of hypertrophic and keloid scars with combined triamcinolone and verapamil: a retrospective study // Eur. J. Plast. Surg. 2018. Vol. 41, № 1. P. 69-80. doi.org/10.1007/s00238-017-1322-y

Kelly A.P. Medical and surgical therapies for keloids // Dermatol. Ther. 2004. Vol. 17. P.212-218. doi.org/10.1111/j.1396-0296.2004.04022.x

Lee J.H., Kim S.E., Lee A.Y. Effects of interferon-alpha2b on keloid treatment with triamcinolone acetonide intralesional injection // Int. J. Dermatol. 2008. Vol. 47, № 2. P.183-186. doi.org/10.1111/j.1365-4632.2008.03426.x

Naeini F.F., Najafian J., Ahmadpour K. Bleomycin tattooing as apromising therapeutic modality in large Keloids and Hypertrophic Scars // Dermatologic Surgery. 2006. Vol. 32, № 8. P. 1023-1030. doi.org/10.1111/j.1524-4725.2006.32225.x

Ogawa R. Keloid and Hypertrophic Scars Are the Result of Chronic Inflammation in the Reticular Dermis // Int. J. Mol. Sci. 2017. Vol. 18, 3. P. 606. doi: 10.3390/ijms18030606

Reinholz M., Poetschke J., Schwaiger H., Epple A., Ruzicka T., Gauglitz G.G. The dermatology life quality index as a means to assess life quality in patients with different scar types // J. Eur. Acad. Dermatol. Venereol. 2015. Vol. 29, № 11. P.2112-2119. doi.org/10.1111/jdv.13135.

Robles D.T., Berg D. Abnormal wound healing: keloids // Clin. Dermatol. 2007. Vol. 25. P. 26-32. doi.org/10.1016/j.clindermatol.2006.09.009

Schneider C.A., Rasband W.S., Eliceiri K.W. NIH Image to ImageJ: 25 years of image analysis // Nature Methods. 2012. Vol. 9. P. 671-675. doi.org/10.1038/nmeth.2089

Srivastava S., Patil A.N., Prakash C, Kumari H. Comparison of Intralesional Triamcinolone Acetonide, 5-Fluorouracil, and Their Combination for the Treatment of Keloids // Adv. Wound Care (New Rochelle). 2017. Vol. 6, № 11. P. 393-400. doi.org/10.1089/wound.2017.0741

Teplyi V., Grebchenko K. Evaluation of the scars’ vascularization using computer processing of the digital images // Skin Res. Technol. 2018. P. 1-6. doi.org/10.1111/srt.12634

Verhiel S., Piatkowski A, van der Hulst R. Mechanism of Action, Efficacy, and Adverse Events of Calcium Antagonists in Hypertrophic Scars and Keloids: A Systematic Review // Dermatologic Surgery. 2015. Vol. 41, № 12. P. 1343-1350. doi.org/10.1097/dss.0000000000000506

Wolfram D., Tzankov A., Pülzl P., Piza-Katzer H. Hypertrophic scars and keloids – a review of their pathophysiology, risk factors, and therapeutic management // Dermatol. Surg. 2009. Vol. 35. P. 171. doi.org/10.1111/j.1524-4725.2008.34406.x

Wollina U. Nonsurgical facial scar revision by Hyaluronidase – A case series // Kosmetische Medizin. 2015. Vol. 36, № 4. P. 164-166.

Yuan F., Shi H., Ji J., Cai Q., Chen X., Yu Y., Liu B., Zhu Z., Zhang J. Capecitabine metronomic chemotherapy inhibits the proliferation of gastric cancer cells through anti-angiogenesis // Oncol. Rep. 2015. Vol. 33, № 4. P. 1753-1762. doi.org/10.3892/or.2015.3765

Zhang G.Y., Cheng T., Luan Q., Liao T., Nie C.L., Zheng X., Xie X.G., Gao W.Y. Vitamin D: a novel therapeutic approach for keloid, an in vitro analysis // Br. J. Dermatol. 2011. Vol. 164. P.729-737. doi.org/10.1111/j.1365-2133.2010.10130.x

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.